
Neuroendocrine Cancer on the Rise: What the Latest Research Shows
By Anna Greene, PhD, NETRF Director of Research A major new study published in JAMA Network Open by Arvind Dasari, MD, MS, and colleagues provides
Announcing the launch of Breakthroughs Today, Cures Tomorrow, our 20th anniversary campaign!

By Anna Greene, PhD, NETRF Director of Research A major new study published in JAMA Network Open by Arvind Dasari, MD, MS, and colleagues provides

By Anna Greene, PhD, NETRF Director of Research We’re excited to share insights from a new ENETS (European Neuroendocrine Tumor Society) position statement, published in

By Anne-Marie Green, NETRF Director of Digital Communications NETRF brought the NET Impact Thrivership & Research Education Program to Alabama for the first time on

By Anna Greene, PhD, NETRF Director of Research Pancreatic neuroendocrine tumors (PanNETs) are rare and tricky. Some grow slowly and never cause trouble, while others

By Anne-Marie Green, Director of Digital Communications As a 19-year veteran educator, Dr. Barbara Dunham’s learning instincts were set in motion when she was diagnosed

Congress recently passed new tax legislation that will change how charitable contributions are treated starting in 2026. While the bill is complex, we want to

We’re proud to celebrate Dr. Suzann Duan, an Assistant Professor in the Department of Pharmaceutical Sciences at UC Irvine, as the recipient of the 2025 Basic/Translational

By Anna Greene, PhD, NETRF Director of Research Dr. Benjamin Viglianti, recipient of a 2023 NETRF Investigator Award, is the senior author of a newly

NETRF is excited to announce that applications are now open for the Nuclear Medicine Pilot Research Grant in Neuroendocrine Tumors (NETs), developed in partnership with

By Anna Greene, PhD, NETRF Director of Research What if small intestine neuroendocrine tumors (SI-NETs), often diagnosed in people over age 60, actually begin decades